Skip to main content

Biomarker-driven surrogate endpoints to accelerate clinical development in immuno-oncology

18 Jun 2024
Salon C
Clinical Development
  • Can biomarker-driven surrogate endpoints be used to accelerate early clinical trials? What are the challenges to get there?
  • How can we identify biomarkers that better capture the mechanism of action and response to I-O agents to be utilized as potential surrogate endpoints?
  • What are the considerations and validation studies that necessary to gain confidence in these biomarkers as surrogate endpoints?
  • How can we better design clinical trials to incorporate relevant biomarkers and decision-making based on these biomarkers?
Industry Expert
Varsha Sundaresan, Oncology Clinical Biomarker Lead - Takeda